IMB Dx

About IMB Dx

IMB Dx, Inc. is a South Korean precision oncology company that has become a publicly traded entity on the KOSDAQ exchange (461030). Founded in 2018, the company is built upon foundational research in circulating tumor DNA (ctDNA) and liquid biopsy applications that began in 2014 by its co-founders, Dr. Tae-You Kim and Dr. Duhee Bang. The leadership team combines deep clinical, scientific, and business expertise. Dr. Tae-You Kim, the CEO, is a medical oncologist from Seoul National University Hospital, while Dr. Duhee Bang serves as the Chief Scientific Advisor, bringing experience from his professorship in chemistry at Yonsei University and a fellowship at Harvard University's George Church Lab.

The core of IMB Dx's business is its liquid biopsy technology, which analyzes trace amounts of cancer-derived genes from a single blood draw. This minimally invasive approach serves as an alternative to traditional tissue biopsies, offering a safer and repeatable method for cancer diagnosis and monitoring. The company operates on a dual business model: providing its tests as a service to major hospitals and selling comprehensive packages that include testing kits and analysis software to biopharmaceutical partners. Its client base includes clinicians, patients, and biopharma companies utilizing the technology for companion diagnostics in clinical trials.

The company's main product line is the AlphaLiquid® platform. Key offerings include AlphaLiquid® 100, a comprehensive genomic profiling test that scans 118 cancer-related genes to help with therapy selection for advanced cancer patients. For post-operative care, CancerDetect™ is an minimal residual disease (MRD) test designed for the early detection of cancer recurrence. Additionally, CancerFind™ is a multi-cancer early detection (MCED) test for screening various cancers. The company has actively pursued global expansion, establishing service agreements in over 20 countries, and has formed strategic partnerships with pharmaceutical giants like AstraZeneca to advance blood-based testing for prostate cancer.